

# 3D Advanced Cell Models at iBET

Building on 35 Years of Scientific Expertise and Innovation

## Human-Relevant Platforms for Drug Discovery & Translational Research

iBET develops next-generation 3D advanced cell models that recapitulate human tissue microenvironments with high physiological fidelity, supporting **drug discovery**, **MoA studies**, **immunotherapy** and **gene-therapy testing**, and **translational research**. These platforms integrate hiPSC-derived systems, primary/patient-derived cells, immune components, multi-omics readouts, and bioreactor technologies, ensuring **robustness**, **reproducibility** and **translational value** for partners.



### What We Offer

- > Human-relevant 3D disease models reflecting brain, liver, heart, kidney and solid-tumor niches.
- > Physiologically accessible systems built on 35+ years of expertise integrating bioprocess engineering and high-resolution analytical tools.
- > Deep analytical insights using multi-omics, imaging, and functional assays to support early decision-making.



### Why Work With Us?

- > Credibility over hype: realistic timelines, dependable data, and clear expectations, aligned with the needs of pharma and biotech.
- > Advanced, ready-to-use models that do not require regulatory validation at early stages, accelerating development.
- > Organ-focused science enabling better mechanistic insights and improved prediction of patient outcomes.
- > Scalable, reproducible workflows supported by bioreactor-based systems.



### Application for Pharma, Biotech & Advanced Therapies

- > Evaluate therapeutic efficacy and safety in human-like microenvironments (biologics, multispecifics, ADCs).
- > Characterize immune modulation and therapeutic resistance mechanisms.
- > Assess AAV vectors, gene-therapy payloads, and innate immune activation in CNS and liver platforms.
- > Use patient-specific models for precision medicine and biomarker-driven strategies.



### What Makes iBET Different

- > 35+ years leadership in physiologically relevant 3D culture systems.
- > Long-standing pharma collaborations across CNS, oncology, liver disease, immunotherapy, and gene therapy.
- > Partnership-driven model, enabling co-development, flexibility and deeper scientific engagement.
- > Proven robustness and reproducibility, providing reliable, consistent, and actionable data

## How can we work together?

- > Targeted feasibility studies
- > Custom model development
- > Mechanistic studies & screening campaigns
- > Co-development projects and long-term partnerships



[Check our toolboxes for scientific insights and data](#)